ʻIke pili: 96.97%（95%CI：83.35%～99.99%）
ʻIkepili pili: 100.00%（95%CI：97.29%～100.00%）
Pono: 99.50%（95%CI：96.94%～99.99%）
Nā hopena wikiwiki i loko o 15-30 minuke Rapid antigen kit AMRDT120
He ho'āʻo wikiwiki no ka ʻike qualitative o ka neutralizing
nā antibodies i ka SARS-CoV-2 a i ʻole kāna mau kano i loko o ke koko holoʻokoʻa, serum, a i ʻole ka plasma.
Hōʻike pūʻolo: 40 T/kit, 20 T/kit, 10 T/kit, 1 T/kit.
ʻIke pili: 96.97%（95%CI：83.35%～99.99%）
ʻIkepili pili: 100.00%（95%CI：97.29%～100.00%）
Pono: 99.50%（95%CI：96.94%～99.99%）
ʻO nā ʻeke pepa, me nā casssttes hoʻāʻo a me nā desiccants *20
Pahu ho'ā'o *20 hue;
Nā mea hoʻolele hoʻolele *20;
Lancet *20
Lodine swab*20
A'o no ka hoohana*1
Nā hopena wikiwiki i loko o 15-30 mau minuke Rapid antigen kit AMRDT120 INTENDED USE
ʻO ka SARS-CoV-2 Neutralizing Antibody Rapid Test (COVID-19 Ab) he immunoassay chromatographic wikiwiki no ka ʻike qualitative o neutralizing antibodies iā SARS-CoV-2 i ke koko holoʻokoʻa, serum, a i ʻole plasma.
Nā hopena wikiwiki i loko o 15-30 minuke Rapid antigen kit AMRDT120 PRINCIPLE
ʻO ka SARS-CoV-2 Neutralizing Antibody Rapid Test (COVID-19 Ab) no ka ʻike ʻana i nā antibodies iā SARS-CoV-2 a i ʻole kāna mau kano.Hoʻopili ʻia ka angiotensin hoʻololi ʻana i ka enzyme-2 (ACE2) i loko o ka ʻāpana laina hoʻāʻo a me ka recombinant receptor-binding domain (RBD) i hui pū ʻia me nā mea kikoʻī.
I ka wā o ka hoʻāʻo ʻana, inā he SARS-CoV-2 neutralizing antibodies i ka specimen, e pane ia me ka protein RBD-particle conjugate a ʻaʻole e pane me ka protein pre-coated ACE2.A laila neʻe ka hui ʻana ma luna o ka membrane chromatographically e ka hana capillary a ʻaʻole e hopu ʻia e ka antigen i uhi mua ʻia.Loaʻa i ka SARS-CoV-2 Neutralizing Antibody Rapid Test (COVID-19 Ab) nā ʻāpana protein RBD-coated.Hoʻopili ʻia ka protein ACE2 ma ka ʻāpana laina hoʻāʻo.
